This session will review the Canadian Cardiovascular Society Position Statement recommendations for the management of ventricular tachycardia and ventricular fibrillation in patients with structural heart disease.
General: All cardiovascular (clinical and research) health professionals Clinical cardiologists General practitioners
At the conclusion of this session, participants will be able to:
understand the importance of a comprehensive initial investigation for patients with VT/VF and which diagnostic tests are appropriate;
initiate appropriate acute therapy for VT/VF;
understand the indications for initiating chronic suppressive therapy for VT/VF in structural heart disease;
understand the pharmacologic, intervention and device management of patients with VT/VF in structural heart disease;
recognize alternative therapies for patients with refractory VT/VF; and